Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Neurocrine Biosciences Inc. (NBIX) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 1,500 employees
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Total Value
-$31,049,143.03
Total Shares
36,349
Average Trade Value
-$316,827.99
Most Active Insider
Gorman Kevin Charles
Total Activity: $28,061,555
Largest Single Transaction
$21,836,503
by Gorman Kevin Charles on Jan 27, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Medical Officer
Officer
|
Feb 14, 2025 | 500 | $57,521 | 35,640 (-1.4%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 1,447 | $168,933 | 18,089 (-8.0%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 2,717 | $10,000 | 18,278 (+14.9%) | Exercise/Conversion | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 1,432 | $167,306 | 16,846 (-8.5%) | Sale | |
|
Chief Scientific Officer
Officer
|
Feb 13, 2025 | 2,690 | $10,000 | 19,536 (+13.8%) | Exercise/Conversion | |
|
Director
|
Feb 13, 2025 | 3,012 | $351,450 | 524,209 (-0.6%) | Sale | |
|
Director
|
Feb 13, 2025 | 5,603 | $10,000 | 527,221 (+1.1%) | Exercise/Conversion | |
|
Director
|
Feb 13, 2025 | 2,832 | $330,465 | 521,618 (-0.5%) | Sale | |
|
Director
|
Feb 13, 2025 | 5,376 | $10,000 | 524,450 (+1.0%) | Exercise/Conversion | |
|
Chief Human Resources Officer
Officer
|
Feb 13, 2025 | 755 | $88,183 | 20,190 (-3.7%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Feb 13, 2025 | 1,401 | $10,000 | 20,945 (+6.7%) | Exercise/Conversion | |
|
Chief Human Resources Officer
Officer
|
Feb 13, 2025 | 796 | $92,946 | 19,544 (-4.1%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Feb 13, 2025 | 1,509 | $10,000 | 20,340 (+7.4%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Feb 13, 2025 | 1,056 | $123,245 | 44,689 (-2.4%) | Sale | |
|
Chief Commercial Officer
Officer
|
Feb 13, 2025 | 1,961 | $10,000 | 45,745 (+4.3%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Feb 13, 2025 | 2,566 | $10,000 | 36,127 (+7.1%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Feb 13, 2025 | 1,352 | $157,979 | 34,775 (-3.9%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 13, 2025 | 2,241 | $10,000 | 37,016 (+6.1%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Feb 13, 2025 | 1,206 | $140,944 | 35,810 (-3.4%) | Sale | |
|
Director
|
Feb 13, 2025 | 13,831 | $1,613,923 | 10,673 (-129.6%) | Sale | |
|
Chief Legal Officer
Officer
|
Feb 13, 2025 | 2,083 | $10,000 | 43,572 (+4.8%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Feb 13, 2025 | 1,086 | $126,790 | 43,405 (-2.5%) | Sale | |
|
Chief Legal Officer
Officer
|
Feb 13, 2025 | 1,098 | $128,202 | 42,474 (-2.6%) | Sale | |
|
Chief Legal Officer
Officer
|
Feb 13, 2025 | 2,017 | $10,000 | 44,491 (+4.5%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Feb 13, 2025 | 1,358 | $10,000 | 4,800 (+28.3%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Feb 13, 2025 | 716 | $83,549 | 4,084 (-17.5%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Feb 13, 2025 | 1,401 | $10,000 | 5,485 (+25.5%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Feb 13, 2025 | 755 | $88,125 | 4,730 (-16.0%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Feb 13, 2025 | 2,566 | $10,000 | 140,224 (+1.8%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Feb 13, 2025 | 2,241 | $10,000 | 141,113 (+1.6%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Feb 13, 2025 | 1,206 | $140,934 | 139,907 (-0.9%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Feb 13, 2025 | 1,352 | $157,974 | 138,872 (-1.0%) | Sale | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 13, 2025 | 1,811 | $10,000 | 3,809 (+47.5%) | Exercise/Conversion | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 13, 2025 | 955 | $111,538 | 2,854 (-33.5%) | Sale | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 13, 2025 | 830 | $96,849 | 3,565 (-23.3%) | Sale | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 2,113 | $10,000 | 35,366 (+6.0%) | Exercise/Conversion | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 13, 2025 | 1,541 | $10,000 | 4,395 (+35.1%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 1,114 | $130,232 | 34,252 (-3.3%) | Sale | |
|
Chief Commercial Officer
Officer
|
Feb 13, 2025 | 2,083 | $10,000 | 44,882 (+4.6%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Feb 13, 2025 | 1,098 | $128,183 | 43,784 (-2.5%) | Sale | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 1,120 | $10,000 | 35,372 (+3.2%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 604 | $70,510 | 34,768 (-1.7%) | Sale | |
|
Chief Medical Officer
Officer
|
Feb 13, 2025 | 1,372 | $10,000 | 36,140 (+3.8%) | Exercise/Conversion | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 10, 2025 | 700 | $82,820 | 1,998 (-35.0%) | Sale | |
|
Chief Commercial Officer
Officer
|
Feb 10, 2025 | 980 | $115,940 | 42,799 (-2.3%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Feb 10, 2025 | 980 | $116,020 | 137,658 (-0.7%) | Sale | |
|
Director
|
Feb 10, 2025 | 2,274 | $269,167 | 519,074 (-0.4%) | Sale | |
|
Chief Medical Officer
Officer
|
Feb 10, 2025 | 980 | $115,853 | 33,253 (-2.9%) | Sale | |
|
Chief Legal Officer
Officer
|
Feb 10, 2025 | 911 | $107,727 | 41,679 (-2.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 10, 2025 | 980 | $115,909 | 33,561 (-2.9%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Feb 10, 2025 | 700 | $82,793 | 18,831 (-3.7%) | Sale | |
|
Director
|
Feb 8, 2025 | 4,318 | $10,000 | 521,348 (+0.8%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Feb 8, 2025 | 1,860 | $10,000 | 34,233 (+5.4%) | Exercise/Conversion | |
|
Chief Human Resources Officer
Officer
|
Feb 8, 2025 | 1,329 | $10,000 | 19,531 (+6.8%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Feb 8, 2025 | 1,860 | $10,000 | 43,779 (+4.2%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Feb 8, 2025 | 1,860 | $10,000 | 34,541 (+5.4%) | Exercise/Conversion | |
|
Chief Corp. Affairs Officer
Officer
|
Feb 8, 2025 | 1,329 | $10,000 | 2,698 (+49.3%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Feb 8, 2025 | 1,727 | $10,000 | 42,590 (+4.1%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Feb 8, 2025 | 1,860 | $10,000 | 138,638 (+1.3%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Feb 3, 2025 | 623 | $93,008 | 3,442 (-18.1%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Feb 3, 2025 | 1,179 | $10,000 | 4,065 (+29.0%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Jan 31, 2025 | 2,373 | $10,000 | 42,113 (+5.6%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Jan 31, 2025 | 1,250 | $191,133 | 40,863 (-3.1%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Jan 31, 2025 | 1,740 | $10,000 | 19,942 (+8.7%) | Exercise/Conversion | |
|
Chief Human Resources Officer
Officer
|
Jan 31, 2025 | 916 | $140,045 | 19,026 (-4.8%) | Sale | |
|
Chief Human Resources Officer
Officer
|
Jan 31, 2025 | 824 | $125,980 | 18,202 (-4.5%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 31, 2025 | 1,283 | $196,136 | 32,681 (-3.9%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 31, 2025 | 1,457 | $222,636 | 32,373 (-4.5%) | Sale | |
|
Director
|
Jan 31, 2025 | 2,707 | $413,967 | 517,030 (-0.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 31, 2025 | 2,927 | $10,000 | 138,319 (+2.1%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Jan 31, 2025 | 1,541 | $235,577 | 136,778 (-1.1%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 31, 2025 | 1,207 | $184,599 | 41,919 (-2.9%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 31, 2025 | 2,294 | $10,000 | 43,126 (+5.3%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Jan 31, 2025 | 2,436 | $10,000 | 33,964 (+7.2%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Jan 31, 2025 | 2,769 | $10,000 | 33,830 (+8.2%) | Exercise/Conversion | |
|
Director
|
Jan 31, 2025 | 5,141 | $10,000 | 519,737 (+1.0%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Jan 31, 2025 | 422 | $64,587 | 2,886 (-14.6%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Jan 31, 2025 | 801 | $10,000 | 3,308 (+24.2%) | Exercise/Conversion | |
|
Chief Scientific Officer
Officer
|
Jan 31, 2025 | 238 | $10,000 | 15,687 (+1.5%) | Exercise/Conversion | |
|
Chief Corp. Affairs Officer
Officer
|
Jan 31, 2025 | 2,096 | $10,000 | 2,473 (+84.8%) | Exercise/Conversion | |
|
Chief Scientific Officer
Officer
|
Jan 31, 2025 | 126 | $19,274 | 15,561 (-0.8%) | Sale | |
|
Chief Corp. Affairs Officer
Officer
|
Jan 31, 2025 | 1,104 | $168,849 | 1,369 (-80.6%) | Sale | |
|
Director
|
Jan 27, 2025 | 146,105 | $21,836,503 | 514,596 (-28.4%) | Sale | |
|
Director
|
Jan 27, 2025 | 146,105 | $4,820,004 | 660,701 (+22.1%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Jan 15, 2025 | 4,812 | $158,748 | 140,204 (+3.4%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Jan 15, 2025 | 60,188 | $1,985,602 | 195,580 (+30.8%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Jan 15, 2025 | 60,188 | $8,516,656 | 135,392 (-44.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 15, 2025 | 4,812 | $680,894 | 135,392 (-3.6%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Dec 31, 2024 | 272 | $21,493 | 2,779 (+9.8%) | Exercise/Conversion | |
|
Chief Regulatory Officer
Officer
|
Dec 31, 2024 | 272 | $37,563 | 2,507 (-10.8%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Dec 17, 2024 | 1,091 | $147,285 | 2,507 (-43.5%) | Sale | |
|
Chief Regulatory Officer
Officer
|
Dec 17, 2024 | 1,091 | $86,211 | 3,598 (+30.3%) | Exercise/Conversion | |
|
Chief Scientific Officer
Officer
|
Nov 29, 2024 | 4,426 | $10,000 | 17,780 (+24.9%) | Exercise/Conversion | |
|
Chief Scientific Officer
Officer
|
Nov 29, 2024 | 2,331 | $294,373 | 15,449 (-15.1%) | Sale | |
|
Chief Medical Officer
Officer
|
Nov 8, 2024 | 1 | $79 | 31,061 (+0.0%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 8, 2024 | 1,233 | $99,935 | 30,089 (+4.1%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 8, 2024 | 971 | $99,916 | 31,060 (+3.1%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Nov 8, 2024 | 5,140 | $399,943 | 28,856 (+17.8%) | Exercise/Conversion |